No Data
ProQR Announces Annual General Meeting of Shareholders to Be Held June 3, 2025
Evercore Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $5
ProQR Therapeutics Initiated With an Outperform at Evercore ISI
ProQR Therapeutics Price Target Announced at $5.00/Share by Evercore ISI Group
Evercore Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $5
ProQR Therapeutics Assumed With an Overweight at Cantor Fitzgerald